Updated on 8 March 2016
Specialized Therapeutics Grants Sublicense for Anti-Emetic Products to Mundipharma for Australia and New Zealand
Singapore: Specialized Therapeutics Pty Ltd and Mundipharma Pty Limited announce a sublicense agreement enabling Mundipharma to assume all commercialization responsibilities for the anti-emetic products ALOXI(palonosetron hydrochloride) and AKYNZEO(netupitant/palonosetron).
Under the terms of the arrangement, Specialized Therapeutics grants Mundipharma exclusive marketing, promotion, distribution and sales rights for the anti-nausea and vomiting pharmaceutical products ALOXI and AKYNZEO in Australia and New Zealand markets.
ALOXI has been approved in Australia for the prevention of nausea and vomiting induced by cytotoxic chemotherapy and has been commercially available in Australia since 2010 under license from Helsinn Healthcare SA, a Swiss pharmaceutical company which has consented to the sublicense agreement.
AKYNZEO is the first fixed combination oral agent targeting two critical signalling pathways associated with chemotherapy induced nausea and vomiting (CINV) by combining netupitant, an NK1 receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist, in a single capsule.
AKYNZEO is also supplied by Helsinn, and was approved by Australia's Therapeutic Goods Administration in May 2015. A submission for reimbursement on the Pharmaceutical Benefits Scheme (PBS) was submitted in 2015 and is nearing completion.